Passage Bio Inc (PASG) - News Archive

Passage Bio Inc. (NASDAQ: PASG), a company dedicated to developing innovative genetic medicines, will be presenting at the upcoming Chardan 8th Annual Genetic Medicines Conference. This prestigious event gathers leaders...

Passage Bio, Inc. a clinical-stage genetic medicine company, is poised to present interim data from its upliFT-D study at the upcoming 14th International Conference on Frontotemporal Dementias (ISFTD2024). This study fo...

Passage Bio Partners with GEMMA Biotherapeutics to Advance Pediatric Gene Therapy ProgramsImagine a world where devastating genetic diseases that afflict children have effective treatments. Thanks to groundbreaking rese...

Passage Bio Receives FDA Endorsement to Broaden upliFT-D Trial for PBFT02 to Encompass FTD-C9orf72 PatientsPassage Bio, a genetic medicines company focused on developing transformative therapies for rare monogenic centr...

Passage Bio to Present at Chardans 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitPHILADELPHIA, April 22, 2024 - Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on...

The biotech sector is witnessing a significant development in the quest to combat neurodegenerative diseases. Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company, has announced initial safety an...

Philadelphia-based genetic medicines company, Passage Bio, Inc. (Nasdaq: PASG), has recently made an exciting announcement stating that it has granted inducement awards to new employees. The clinical-stage company, whic...